This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Pemphigus Vulgaris Overview
- Therapeutics Development
- Pipeline Products for Pemphigus Vulgaris - Overview
- Pipeline Products for Pemphigus Vulgaris - Comparative Analysis
- Pemphigus Vulgaris - Therapeutics under Development by Companies
- Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes
- Pemphigus Vulgaris Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Pemphigus Vulgaris - Products under Development by Companies
- Pemphigus Vulgaris - Products under Investigation by Universities/Institutes
- Pemphigus Vulgaris - Companies Involved in Therapeutics Development
- Almirall, S.A.
- Biogen, Inc.
- F. Hoffmann-La Roche Ltd.
- HanAll Biopharma Co., Ltd.
- Immunomedics, Inc.
- Novartis AG
- Principia Biopharma Inc.
For more information visit http://www.researchandmarkets.com/research/llf76f/pemphigus